021-51111890
购物车（）
sales@molnova.cn
Cediranib
CAS No. 288383-20-0
Cediranib ( AZD2171;AZD 2171;AZD-2171 )
产品货号. M13883 CAS No. 288383-20-0
A highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥284 | 有现货 |
|
| 5MG | ￥462 | 有现货 |
|
| 10MG | ￥680 | 有现货 |
|
| 25MG | ￥1118 | 有现货 |
|
| 50MG | ￥1515 | 有现货 |
|
| 100MG | ￥2163 | 有现货 |
|
| 200MG | ￥3945 | 有现货 |
|
| 500MG | ￥6334 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Cediranib
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively.
-
产品描述A highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively; also inhibits c-Kit and PDGFRβ with IC50 of 2 and 5 nM, >36-fold selectivity over PDGFR-α, >1000-fold over Flt-3 and EGFR; inhibits VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM in human umbilical vein endothelial cells; inhibits angiogenesis, neovascular survival and tumor growth in vivo. Ovarian Cancer Phase 3 Clinical
-
同义词AZD2171;AZD 2171;AZD-2171
-
通路Angiogenesis
-
靶点VEGFR
-
受体c-Kit;PDGFRβ;VEGFR1/FLT1;VEGFR2/KDR;VEGFR3/FLT4
-
研究领域Cancer
-
适应症Ovarian Cancer
化学信息
-
CAS Number288383-20-0
-
分子量450.51
-
分子式C25H27FN4O3
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 49 mg/mL
-
SMILESCOC1=C(OCCCN2CCCC2)C=C2N=CN=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C2=C1
-
化学全称Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Wedge SR, et al. Cancer Res. 2005 May 15;65(10):4389-400.
2. Denduluri N, et al. Clin Breast Cancer. 2005 Dec;6(5):460-3.
3. Batchelor TT, et al. Cancer Cell. 2007 Jan;11(1):83-95.
4. Cao C, et al. Cancer Res. 2006 Dec 1;66(23):11409-15.
2. Denduluri N, et al. Clin Breast Cancer. 2005 Dec;6(5):460-3.
3. Batchelor TT, et al. Cancer Cell. 2007 Jan;11(1):83-95.
4. Cao C, et al. Cancer Res. 2006 Dec 1;66(23):11409-15.
产品手册
关联产品
-
Linifanib
A potent multi-RTKs inhibitor of members of VEGFR and PDGFR families.
-
Lenvatinib
Lenvatinib (E7080) is a multitargeted kinase inhibitor with IC50s of 4/5.2/22/46 nM for VEGFR2/VEGFR3/VEGFR1/FGFR1 in cell free assays.
-
SU14813 maleate
A broad-spectrum RTKs inhibitor with IC50 ranging from 2 to 50 nM for VEGFR-1, VEGFR-2, PDGFRs, KIT, FLT3, and CSF1R/FMS.
